BioVersys appoints Dr. William Jenkins a special advisor and board member elect
Basel, Switzerland. August 24, 2021, 9am CEST
BioVersys AG appoints Dr. William Jenkins as special advisor and board member elect
BioVersys AG, a privately owned clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of small molecules for multidrug-resistant bacterial infections with applications in antimicrobial resistance (AMR) and targeted microbiome modulation, announced today that Dr. William Jenkins has joined the company as a special advisor and board member elect.
Dr. Jenkins is an independent healthcare advisor with over 40 years’ experience. He brings extensive clinical development and regulatory knowledge, along with strategic business experience, that will complement and strengthen BioVersys’ Board of Directors. He has served on the Board of Directors of numerous pharmaceutical and biotech companies and has been involved in corporate transactions ranging from mergers & acquisitions, demergers and IPOs to licensing deals. Dr. Jenkins was previously the Global Head of Clinical Development and Regulatory Affairs of Novartis, Head of Medicine of Ciba-Geigy and Head of Worldwide Clinical Research of the Glaxo Group. Before joining the pharmaceutical industry, Dr. Jenkins was Principal Medical Officer and a Deputy Head of the Medicines Division of the UK Department of Health where he was also the UK representative to the CPMP on Adverse Drug Reactions.
Dr. Marc Gitzinger, CEO and founder of BioVersys: “We are delighted that Dr. Jenkins will bring his many years of invaluable experience in clinical drug development to BioVersys where he will complement the current members of the Board of Directors and management team. We are looking forward to his contribution to BioVersys, as we continue to deliver on our corporate objectives and develop urgently needed novel antimicrobial therapies for patients with unmet medical needs.”
Dr. William Jenkins, board member elect: “At a time when the world is struggling to contain Covid-19 and related infections, the lack of working antibiotics has never been more evident. AMR has placed global healthcare systems under tremendous pressure as current day antibiotics become obsolete. I am very pleased to join BioVersys, which has one of the most attractive AMR portfolios in the industry, and contribute towards achieving the goals of the company to deliver innovative life-saving antimicrobial solutions.”
Dr. Seng Chin Mah, Chairman of BioVersys: “I am delighted to welcome William to BioVersys as a board member elect. He brings a wealth of experience across the drug development spectrum and business strategies through to corporate transactions which will greatly benefit BioVersys as we prepare to transition to Phase 2 and a potential IPO. His appointment is part of a series of relevant and timely skill sets that we have added to the company this year. We remain committed to investing in the right human capital critical for the success of the company and to ultimately return stakeholder value.”